Article metrics

Download PDFPDF
Randomised controlled trial
Clinicians should assess the benefits and risks of using bezlotoxumab for reducing the risk of recurrent Clostridium difficile infection

 

Online download statistics by month:

Online download statistics by month: July 2017 to March 2024

AbstractFullPdf
Jul 20174083229
Aug 20175555720
Sep 20176822111
Oct 2017193165
Nov 2017100164
Dec 20175495
Jan 20186530
Feb 20186764
Mar 201883138
Apr 20184231
May 20184621
Jun 20186343
Jul 20184921
Aug 20184820
Sep 20188053
Oct 20181930
Nov 20184663
Dec 20182300
Jan 20195753
Feb 20192431
Mar 20193143
Apr 20191122
May 20191403
Jun 20193114
Jul 20194645
Aug 20192030
Sep 20192300
Oct 20193000
Nov 2019510
Dec 20192911
Jan 20202013
Feb 20203511
Mar 2020800
Apr 20201002
May 20201900
Jun 2020712
Jul 20203010
Aug 2020600
Sep 20203400
Oct 20203610
Nov 20201800
Dec 20201831
Jan 20212321
Feb 20212000
Mar 20211020
Apr 20211613
May 20212700
Aug 2021400
Sep 2021331
Oct 20212610
Nov 20211400
Dec 20212810
Jan 20223000
Feb 20223110
Mar 20222111
Apr 20224201
May 20224810
Jun 20224200
Jul 20223800
Aug 20225520
Sep 20225502
Oct 20226910
Nov 20227221
Dec 20221900
Jan 20231800
Feb 20235701
Mar 2023921
Apr 2023700
May 20231800
Jun 2023600
Jul 20231300
Aug 20231000
Sep 20231000
Oct 20231400
Nov 20233720
Dec 20233500
Jan 20242711
Feb 20242312
Mar 20242902
Total4191256146